These findings suggest that bispecific antibodies and ADCs that target HER2 and PRLR may offer a promising approach for improving the efficacy of HER2-targeted therapies in HER2-positive cancers that co-express PRLR [95]. The gene discussed is ERBB2; the disease is cancer.